Viveve Medical (NASDAQ:VIVE)‘s stock had its “buy” rating reissued by Ladenburg Thalmann Financial Services in a research note issued on Thursday.
A number of other brokerages have also issued reports on VIVE. Cowen set a $11.00 price target on Viveve Medical and gave the stock a “buy” rating in a research note on Monday, October 23rd. ValuEngine lowered Viveve Medical from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Mizuho reiterated a “buy” rating and issued a $10.00 price target on shares of Viveve Medical in a research note on Friday. Finally, Northland Securities began coverage on Viveve Medical in a research note on Friday. They issued an “outperform” rating and a $8.00 price target for the company. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $10.00.
Shares of Viveve Medical (VIVE) traded down $0.22 during mid-day trading on Thursday, reaching $4.97. The company’s stock had a trading volume of 250,000 shares, compared to its average volume of 138,267. Viveve Medical has a 1-year low of $3.75 and a 1-year high of $11.16. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.89 and a quick ratio of 3.63. The stock has a market cap of $96.55, a price-to-earnings ratio of -2.31 and a beta of -0.67.
Several institutional investors have recently modified their holdings of the company. HighTower Advisors LLC grew its position in shares of Viveve Medical by 33.2% during the second quarter. HighTower Advisors LLC now owns 1,723,751 shares of the company’s stock valued at $12,379,000 after purchasing an additional 430,033 shares in the last quarter. RTW Investments LP grew its position in shares of Viveve Medical by 18.8% during the third quarter. RTW Investments LP now owns 1,473,028 shares of the company’s stock valued at $7,719,000 after purchasing an additional 233,585 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Viveve Medical by 135.4% during the second quarter. Vanguard Group Inc. now owns 450,142 shares of the company’s stock valued at $3,232,000 after purchasing an additional 258,912 shares in the last quarter. Manatuck Hill Partners LLC grew its position in shares of Viveve Medical by 128.6% during the second quarter. Manatuck Hill Partners LLC now owns 400,000 shares of the company’s stock valued at $2,872,000 after purchasing an additional 225,000 shares in the last quarter. Finally, ING Groep NV grew its position in shares of Viveve Medical by 93.7% during the third quarter. ING Groep NV now owns 325,000 shares of the company’s stock valued at $1,703,000 after purchasing an additional 157,200 shares in the last quarter. Hedge funds and other institutional investors own 66.90% of the company’s stock.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.